These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 23029232)

  • 1. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.
    Hashemi H; Pouyanfard S; Bandehpour M; Noroozbabaei Z; Kazemi B; Saelens X; Mokhtari-Azad T
    PLoS One; 2012; 7(9):e45765. PubMed ID: 23029232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.
    Zhao G; Lin Y; Du L; Guan J; Sun S; Sui H; Kou Z; Chan CC; Guo Y; Jiang S; Zheng BJ; Zhou Y
    Virol J; 2010 Jan; 7():9. PubMed ID: 20082709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of immunity induced by M2e of influenza virus.
    Wu F; Huang JH; Yuan XY; Huang WS; Chen YH
    Vaccine; 2007 Dec; 25(52):8868-73. PubMed ID: 18061317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Construction and immunogenicity of recombinant bacteriophage T7 vaccine expressing M2e peptides of avian influenza virus].
    Xu H; Wang YW; Tang YH; Zheng QS; Hou JB
    Bing Du Xue Bao; 2013 Jun; 29(4):376-81. PubMed ID: 23895000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
    Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS
    Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
    Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
    Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.
    Lee YN; Lee YT; Kim MC; Hwang HS; Lee JS; Kim KH; Kang SM
    Immunology; 2014 Oct; 143(2):300-9. PubMed ID: 24773389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
    Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W
    Virol J; 2007 Oct; 4():118. PubMed ID: 17974006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
    Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
    Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.
    Zhao G; Sun S; Du L; Xiao W; Ru Z; Kou Z; Guo Y; Yu H; Jiang S; Lone Y; Zheng BJ; Zhou Y
    Virol J; 2010 Jul; 7():151. PubMed ID: 20624292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
    Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
    Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An influenza A virus vaccine based on an M2e-modified alphavirus.
    Krishnavajhala HR; Williams J; Heidner H
    Arch Virol; 2018 Feb; 163(2):483-488. PubMed ID: 29079954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.
    Shim BS; Choi YK; Yun CH; Lee EG; Jeon YS; Park SM; Cheon IS; Joo DH; Cho CH; Song MS; Seo SU; Byun YH; Park HJ; Poo H; Seong BL; Kim JO; Nguyen HH; Stadler K; Kim DW; Hong KJ; Czerkinsky C; Song MK
    PLoS One; 2011; 6(11):e27953. PubMed ID: 22140491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
    Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
    Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin.
    Mardanova ES; Kotlyarov RY; Kuprianov VV; Stepanova LA; Tsybalova LM; Lomonossoff GP; Ravin NV
    Bioengineered; 2016; 7(1):28-32. PubMed ID: 26710263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W; Huang B; Wang X; Tan W; Ruan L
    Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice.
    Ameghi A; Pilehvar-Soltanahmadi Y; Baradaran B; Barzegar A; Taghizadeh M; Zarghami N; Aghaiypour K
    Viral Immunol; 2016 May; 29(4):228-34. PubMed ID: 27058011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.